TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,218.00▼ 7.87%TCS₹2,100.00▼ 8.85%HDFCBANK₹711.45▼ 0.09%ICICIBANK₹1,342.80▼ 5.65%INFY₹1,013.85▼ 10.28%HINDUNILVR₹1,895.20▼ 3.96%ITC₹266.70▲ 0.98%SBIN₹958.75▼ 5.64%BHARTIARTL₹1,810.50▼ 1.60%KOTAKBANK₹431.90▲ 1.74%LT₹3,770.00▼ 4.90%AXISBANK₹1,248.00▼ 1.96%ASIANPAINT₹2,424.20▼ 4.08%MARUTI₹11,625.00▼ 8.42%AAPL$333.63▲ 4.27%MSFT$529.30▲ 5.92%GOOGL$347.68▲ 2.72%AMZN$256.29▼ 0.86%NVDA$239.24▲ 3.85%META$738.88▲ 19.80%TSLA$380.68▲ 7.51%BRK-B$505.54▼ 0.10%JPM$331.28▼ 7.63%V$370.64▼ 1.18%
RELIANCE₹1,218.00▼ 7.87%TCS₹2,100.00▼ 8.85%HDFCBANK₹711.45▼ 0.09%ICICIBANK₹1,342.80▼ 5.65%INFY₹1,013.85▼ 10.28%HINDUNILVR₹1,895.20▼ 3.96%ITC₹266.70▲ 0.98%SBIN₹958.75▼ 5.64%BHARTIARTL₹1,810.50▼ 1.60%KOTAKBANK₹431.90▲ 1.74%LT₹3,770.00▼ 4.90%AXISBANK₹1,248.00▼ 1.96%ASIANPAINT₹2,424.20▼ 4.08%MARUTI₹11,625.00▼ 8.42%AAPL$333.63▲ 4.27%MSFT$529.30▲ 5.92%GOOGL$347.68▲ 2.72%AMZN$256.29▼ 0.86%NVDA$239.24▲ 3.85%META$738.88▲ 19.80%TSLA$380.68▲ 7.51%BRK-B$505.54▼ 0.10%JPM$331.28▼ 7.63%V$370.64▼ 1.18%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AZN

AstraZeneca PLC Ordinary Shares

NYSE
$158.61
▼ $4.09 (-2.5%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 06 Oct 2026
H $207.30L $153.41-18.2%
$207.3$196.52$185.74$174.97$164.19$153.41$158.61
RSI (14)
Intraday · 15-minBuy+15RSI 59UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong sell-60
RSI (14)42
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$154.81
Resistance
$169.35
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-01-02 → 2026-10-06

Strategy return
-6.1%
Buy & hold
-13.4%
Trades
6
Win rate
33%

$100,000.00 invested would be worth $93,933.77 (-6.1%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AstraZeneca PLC· Drug Manufacturers - General

source: yahoo

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
96,100
Headquarters

Fundamentals

source: yahoo
Market cap
$245.99B
P/E
23.7
P/B
4.9
EPS
$6.69
Div yield
2.0%
Profit margin
17.0%
ROE
22.0%
Debt / Equity
0.64
Beta
0.21
52-week range
$153.41 – $212.71
52-week low · $153.419% of rangehigh · $212.71

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive2↑ · 0↓ · 6–
  • Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now— Neutral
    BeInCrypto · 07 Oct 2026
  • Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider— Neutral
    Zacks · 06 Oct 2026
  • Multiply Labs Raises $75 Million Series B to Close the Gap Between Drug Discovery and Drug Manufacturing▲ Positive
    Business Wire · 06 Oct 2026
  • Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
Cambridge, United Kingdom
www.astrazeneca.com ↗
— Neutral
Zacks · 06 Oct 2026
  • Citi raises AstraZeneca target to £186 as tozorakimab prospects improve▲ Positive
    Proactive · 06 Oct 2026
  • AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos— Neutral
    Quartz · 06 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.